Hustinx R - Search Results

1

Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL).

Cottereau AS, Becker S, Broussais F, Casasnovas O, Kanoun S, Roques M, Charrier N, Bertrand S, Delarue R, Bonnet C, Hustinx R, Gaulard P, de Leval L, Vera P, Itti E, Mounier N, Haioun C, Tilly H, Meignan M. Cottereau AS, et al. Among authors: hustinx r. Ann Oncol. 2016 Apr;27(4):719-24. doi: 10.1093/annonc/mdw011. Epub 2016 Jan 19. Ann Oncol. 2016. PMID: 26787236 Free article.

2

Clinical evaluation of whole-body 18F-fluorodeoxyglucose positron emission tomography in the detection of liver metastases.

Hustinx R, Paulus P, Jacquet N, Jerusalem G, Bury T, Rigo P. Hustinx R, et al. Ann Oncol. 1998 Apr;9(4):397-401. doi: 10.1023/a:1008290027419. Ann Oncol. 1998. PMID: 9636830 Free article. Clinical Trial.

3

Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL).

Jerusalem G, Beguin Y, Najjar F, Hustinx R, Fassotte MF, Rigo P, Fillet G. Jerusalem G, et al. Among authors: hustinx r. Ann Oncol. 2001 Jun;12(6):825-30. doi: 10.1023/a:1011169332265. Ann Oncol. 2001. PMID: 11484959 Free article. Clinical Trial.

4

The value of positron emission tomography (PET) imaging in disease staging and therapy assessment.

Jerusalem G, Hustinx R, Beguin Y, Fillet G. Jerusalem G, et al. Among authors: hustinx r. Ann Oncol. 2002;13 Suppl 4:227-34. doi: 10.1093/annonc/mdf664. Ann Oncol. 2002. PMID: 12401695 Free article. Review. No abstract available.

5

Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease.

Jerusalem G, Beguin Y, Fassotte MF, Belhocine T, Hustinx R, Rigo P, Fillet G. Jerusalem G, et al. Among authors: hustinx r. Ann Oncol. 2003 Jan;14(1):123-30. doi: 10.1093/annonc/mdg011. Ann Oncol. 2003. PMID: 12488304 Free article.

6

Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.

Hustinx R, Lemaire C, Jerusalem G, Moreau P, Cataldo D, Duysinx B, Aerts J, Fassotte MF, Foidart J, Luxen A. Hustinx R, et al. J Nucl Med. 2003 Apr;44(4):533-9. J Nucl Med. 2003. PMID: 12679396 Free article. Clinical Trial.

7

Within-patient variability of (18)F-FDG: standardized uptake values in normal tissues.

Paquet N, Albert A, Foidart J, Hustinx R. Paquet N, et al. Among authors: hustinx r. J Nucl Med. 2004 May;45(5):784-8. J Nucl Med. 2004. PMID: 15136627 Free article.

8

Assessment of disease activity in rheumatoid arthritis with (18)F-FDG PET.

Beckers C, Ribbens C, André B, Marcelis S, Kaye O, Mathy L, Kaiser MJ, Hustinx R, Foidart J, Malaise MG. Beckers C, et al. Among authors: hustinx r. J Nucl Med. 2004 Jun;45(6):956-64. J Nucl Med. 2004. PMID: 15181130 Free article. Clinical Trial.

9

18F-FDG PET in children with lymphomas.

Depas G, De Barsy C, Jerusalem G, Hoyoux C, Dresse MF, Fassotte MF, Paquet N, Foidart J, Rigo P, Hustinx R. Depas G, et al. Among authors: hustinx r. Eur J Nucl Med Mol Imaging. 2005 Jan;32(1):31-8. doi: 10.1007/s00259-004-1604-z. Epub 2004 Jul 24. Eur J Nucl Med Mol Imaging. 2005. PMID: 15605288

10

Clinical added-value of 18FDG PET in neuroendocrine-merkel cell carcinoma.

Belhocine T, Pierard GE, Frühling J, Letesson G, Bolle S, Hustinx R, Dargent JL, Flamen P, Rigo P. Belhocine T, et al. Among authors: hustinx r. Oncol Rep. 2006 Aug;16(2):347-52. Oncol Rep. 2006. PMID: 16820914

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

247 results

Search Page